000			03139cam a2200349 a 4500
003			EG-GiCUC
005			20250223031350.0
008			151208s2015 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.12.02.Ph.D.2015.Su.P
100	0		_aSuzan Hamdy Mohamed Elmasry
245	1	4	_aThe possible role of aberrant promoter methylation in chronic active hepatitis patients and its relation with interferon therapy response / _cSuzan Hamdy Mohamed Elmasry ; Supervised Hamed Abdelfatah Dabaon , Abdelrahman Nabawy Zekri , Mohamed Aly Eldesouky
246	1	5	_aدور ميثلة البادئ الضال في مرضي الإلتهاب الكبدي الوبائى المزمن النشط و علاقته بالإستجابة للعلاج بالأنترفيرون
260			_aCairo : _bSuzan Hamdy Mohamed Elmasry , _c2015
300			_a143 P. : _bcharts ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Science - Department of Biochemistry
520			_aHepatitis C virus (HCV) is the cause of a significant proportion of cases of chronic liver disease, Hepatocellular carcinoma (HCC) and deaths from liver disease. Egypt has the highest prevalence of HCV worldwide (15%) and the highest prevalence of HCV genotype 4, which is responsible for almost 90% of infections.DNA methylation plays a critical role in the control of important cellular processes and potentiates the progression of HCV related liver disease and affects its response to therapy. Our study aims to show the impact of promoter methylation (PM) of some genes {APC )Adenomatous polyposis coli(, P14ARF, P73, DAPK( Death-associated protein kinase), RASSF1A(Ras-Association Domain Family 1) and O6MGMT(methylguanine-DNA methyltransferase)} on the antiviral response to antiviral therapy and its relation to the presence of fibrosis in HCV-4 infected patients from Egypt. Clinical, laboratory and histopathological data of 53 HCV-4 infected patients who were subjected to combined antiviral therapy were collected; patients were classified according to their response to treatment into: Group I: This group included 24 CH patients non-responded to IFN treatment after 27 weeks positive for HCV infection by RT-PCR. Group II: This group included 29 CH patients responded to IFN treatment after 72 weeks negative for HCV infection by RT-PCR. The main results of this study are the PM of some Tumor Suppressor genes increases in chronic active HCV-4.However, only O6MGMT gene can be used as a predictor of antiviral response and RASSF1A gene as a marker of mild fibrosis grade in the studied patients
530			_aIssued also as CD
653		4	_aAdenomatous polyposis coli
653		4	_aHepatitis C virus
653		4	_aHepatocellular carcinoma
700	0		_aAbdelrahman Nabawy Zekri, _eSupervisor
700	0		_aHamed Abdelfatah Dabaon , _eSupervisor
700	0		_aMohamed Aly Eldesouky , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aEnas _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c53837 _d53837